Viewing Study NCT03894150

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:13 PM
Ignite Modification Date: 2026-02-26 @ 3:17 AM
Study NCT ID: NCT03894150
Status: COMPLETED
Last Update Posted: 2024-05-14
First Post: 2019-03-26
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.
Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Refractory or Recurrent CD30+ Hematologic Malignancies View
Keywords: